Role of rituximab in the treatment of systemic sclerosis: A literature review
Modern Rheumatology · 2023
DOI: 10.1093/mr/road040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Hajime Yoshifuji und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Scleroderma, Systemic, Scleroderma, Diffuse. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
This literature review aimed to evaluate the effectiveness of rituximab (RTX) in patients with systemic sclerosis (SSc). PubMed was searched for articles, published through 31 March 2022, on any controlled studies using RTX in the treatment of SSc. Of 85 identified articles, 9 were selected by title/abstract screening and full text examination. All nine articles reported outcomes of forced vital capacity (%FVC), and seven reported those of modified Rodnan skin scores (mRSS). The results showed that among the seven controlled studies evaluating skin lesions in patients with SSc, four showed a significant improvement of mRSS by RTX when compared with a control group, whereas three showed no significant effect. Among the nine controlled studies evaluating lung lesions, five showed a significant improvement of %FVC compared with a control group, whereas four showed no significant effect. In conclusion, RTX may be effective in the treatment of skin and lung lesions in patients with SSc. The profiles of SSc patients for whom RTX was indicated were unclear, although patients with diffuse cutaneous SSc and those positive for anti-topoisomerase I antibody were considered potential targets. Additional studies are needed to assess the long-term effectiveness of RTX in the treatment of patients with SSc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Allergy and Rheumatology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan.
- Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan.
- Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine, Aichi, Japan.
Zitieren
APA
Yoshifuji, H., Yomono, K., Yamano, Y., Kondoh, Y., & Yasuoka, H. (2023). Role of rituximab in the treatment of systemic sclerosis: A literature review. Modern Rheumatology. https://doi.org/10.1093/mr/road040
Vancouver
Yoshifuji H, Yomono K, Yamano Y, Kondoh Y, Yasuoka H. Role of rituximab in the treatment of systemic sclerosis: A literature review. Modern Rheumatology. 2023. doi:10.1093/mr/road040
BibTeX
@article{Yoshifuji2023,
author = {Yoshifuji, Hajime and Yomono, Keina and Yamano, Yasuhiko and Kondoh, Yasuhiro and Yasuoka, Hidekata},
title = {Role of rituximab in the treatment of systemic sclerosis: A literature review},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/road040}
}
EUVIMED